Form 4: ADAR1 Capital Increases Stake in Rallybio Corp

ADAR1 Capital Management, LLC reported the acquisition of 16,209 shares of Rallybio Corp common stock across multiple transactions.

Summary

• ADAR1 Capital Management, LLC and Daniel Schneeberger acquired a total of 16,209 shares of Rallybio Corp (RLYB) common stock.
• Purchases occurred on May 18, 2026, and May 19, 2026.
• The total beneficial ownership following these transactions is 926,352 shares.
• Shares were acquired at weighted average prices ranging from $13.80 to $13.98 per share.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive signal, as it reflects active buying interest from a significant shareholder, which typically indicates confidence in the company's direction.

Positives

• Increased investment from a 10% owner signals confidence in the issuer's long-term prospects.
• Consistent accumulation of shares by a major institutional holder.

Negatives

• None identified in this filing.

Risks

• Market volatility affecting the value of the acquired equity.
• Concentration risk for the reporting person regarding their position in Rallybio Corp.

Future Outlook

No specific forward-looking guidance provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that institutional accumulation of biotech equities often precedes strategic developments or reflects a belief in the undervaluation of the company's clinical pipeline.

Comparison to Industry Standards

• The purchase of shares by a 10% owner is consistent with standard capital market activity for institutional investors maintaining or increasing positions in small-cap biotech firms.

Stakeholder Impact

• Shareholders may view the increased stake as a vote of confidence in the company's management and pipeline.

Next Steps

• Continued monitoring of SEC filings for further changes in beneficial ownership by ADAR1 Capital Management.

Key Dates

Keywords

Rallybio, RLYB, ADAR1 Capital, Insider Trading, Form 4, Beneficial Ownership